<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Pasteur Institute</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Logo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Paris, France</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Private Non-profit Foundation</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.pasteur.fr" target="_blank">https://www.pasteur.fr</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Neuroinflammation](/mechanisms/neuroinflammation), [Prion Diseases](/diseases/prion)</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1887</td>
</tr>
</table>
The Pasteur Institute, founded in 1887 by Louis Pasteur, stands as one of the world's premier biomedical research institutions. Located in Paris, France, the institute was established to study rabies and has since expanded to encompass a broad spectrum of infectious diseases, immunology, and more recently, neurodegenerative disease research.
Pasteur Institute is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Pasteur Institute</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Logo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Paris, France</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Private Non-profit Foundation</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.pasteur.fr" target="_blank">https://www.pasteur.fr</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Neuroinflammation](/mechanisms/neuroinflammation), [Prion Diseases](/diseases/prion)</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1887</td>
</tr>
</table>
The Pasteur Institute, founded in 1887 by Louis Pasteur, stands as one of the world's premier biomedical research institutions. Located in Paris, France, the institute was established to study rabies and has since expanded to encompass a broad spectrum of infectious diseases, immunology, and more recently, neurodegenerative disease research.
Pasteur Institute is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Pasteur Institute is a French private non-profit foundation dedicated to the study of biology, microorganisms, diseases, and vaccines. Founded in 1887 by Louis Pasteur, the institute is one of the world's leading research institutions in microbiology and infectious diseases.<sup>[1]</sup>
While primarily known for infectious disease research, Pasteur Institute has expanded its mission to include neurodegenerative disease research, particularly in the areas of neuroinflammation, protein aggregation, and prion diseases.
Pasteur Institute hosts research units focused on:
Research in cellular neuroscience includes:
The institute investigates fundamental mechanisms shared across neurodegenerative diseases:
Protein Misfolding: Understanding how normal proteins misfold and aggregate into toxic species.
Oxidative Stress: Role of reactive oxygen species in neuronal damage.
Energy Metabolism: Mitochondrial dysfunction and cellular energy deficits.
Calcium Dysregulation: Disrupted calcium signaling in neurons and glia.
The Pasteur Institute is a world leader in prion disease research:
Research on neuroimmune interactions:
| Disease | Research Focus |
|---------|----------------|
| Prion Diseases | Prion propagation, strain diversity, therapy |
| Alzheimer's Disease | Amyloid, [tau](/proteins/tau), neuroinflammation |
| Parkinson's Disease | [Alpha-synuclein](/proteins/alpha-synuclein), neuroinflammation |
| Multiple Sclerosis | Autoimmunity, demyelination |
Pasteur Institute researchers have characterized distinct prion strains and their mechanisms of propagation, leading to improved diagnostic methods and therapeutic strategies[@aguzzi2023]. The work of Simoneau et al. (2023) on prion strain typing using cell-free conversion assays has advanced the field's understanding of strain diversity[@simoneau2023].
Discovery of novel neuroinflammatory pathways that contribute to neurodegeneration, identifying potential therapeutic targets for Alzheimer's and Parkinson's diseases[@heneka2025][@weeks2023]. Bauer et al. (2022) reviewed the comprehensive role of neuroinflammation in neurodegenerative diseases, establishing mechanistic frameworks for understanding these processes[@bauer2022].
Pioneering work on [microglia](/cell-types/microglia-neuroinflammation) activation and their dual role in both protecting and damaging the brain in neurodegenerative conditions. Caillaud et al. (2022) demonstrated that microglia have a dual role in prion disease—both protecting the brain and contributing to pathology[@caillaud2022]. Combrisson et al. (2023) applied single-cell analysis to characterize microglia heterogeneity in neurodegenerative diseases[@combrisson2023].
The Prion Research Unit at Pasteur Institute represents one of the world's leading programs in prion disease research. Since the emergence of bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD) in the 1990s, Pasteur Institute has been at the forefront of understanding these fatal neurodegenerative disorders.
Research on sporadic, familial, and iatrogenic CJD encompasses:
Epidemiology: Brandel et al. (2022) provided an updated epidemiological analysis of CJD in France, documenting incidence patterns and risk factors[@brandel2022]. Peyraud et al. (2022) reviewed the clinical and epidemiological features of human prion diseases globally[@peyraud2022].
Pathogenesis: Studies on the cellular and molecular mechanisms of prion propagation, including work by Aguzzi et al. (2023) on mechanisms and therapeutic targets[@aguzzi2023].
Diagnostics: Development of improved diagnostic tools including CSF biomarkers and brain imaging markers.
Research on vCJD, the human disease linked to BSE exposure, has included:
The institute investigates naturally occurring and experimental animal prion diseases including:
Research on prion disease therapeutics includes:
Pasteur Institute researchers have made fundamental contributions to understanding microglia in neurodegenerative diseases:
Activation States: Studies defining the spectrum of microglia activation states, from pro-inflammatory (M1) to neuroprotective (M2) phenotypes.
Dual Role: Recognition that microglia can both protect neurons and contribute to pathology depending on context and activation state[@caillaud2022].
Therapeutic Targeting: Development of strategies to modulate microglia toward neuroprotective phenotypes.
Research on inflammatory mediators in neurodegeneration:
Studies on BBB dysfunction in neurodegenerative conditions:
Belzung et al. (2023) explored the relationship between neuroinflammation and depression, a common non-motor symptom in Parkinson's disease and other neurodegenerative conditions[@belzung2023].
Research on the core pathological features of AD:
Chasseigneaux et al. (2023) investigated amyloid-beta and tau pathology in early-onset Alzheimer's disease, identifying differences from late-onset forms[@chasseigneaux2023].
Amyloid Hypothesis: Studies on amyloid-beta generation, aggregation, and toxicity.
Tau Pathology: Research on tau phosphorylation, aggregation, and propagation.
Interaction: Understanding how amyloid and tau pathologies interact.
The institute has made significant contributions to understanding neuroinflammation in AD:
Jaouen et al. (2024) reviewed blood biomarkers for neurodegenerative diseases, including current status and future directions[@jaouen2024].
Studies on the protein central to PD pathogenesis:
Lazaro et al. (2023) used animal models to investigate alpha-synuclein aggregation in Parkinson's disease, providing new insights into disease mechanisms[@lazaro2023].
Research areas include:
Investigation of inflammatory processes in PD:
Research on atypical parkinsonian disorders:
Pasteur Institute researchers use advanced techniques to understand protein structure:
Cryo-Electron Microscopy: Determining the structure of amyloid fibrils and prion proteins at near-atomic resolution.
X-ray Crystallography: Solving the structure of protein domains involved in aggregation.
NMR Spectroscopy: Studying protein dynamics and interactions in solution.
The institute maintains screening facilities for drug discovery:
Pasteur Institute participates in clinical trials for:
Rodriguez et al. (2024) reviewed CRISPR-based therapies for neurodegenerative diseases, presenting current approaches and future directions[@rodriguez2024].
Pasteur Institute offers a prestigious international PhD program in microbiology and neuroscience:
Research fellowships in specialized units:
Intensive courses in microbiology and immunology open to international students:
The Pasteur Institute network comprises 32 institutes worldwide:
The international network enables:
Horizon Europe projects and other EU-funded research initiatives:
Partnerships with US National Institutes of Health:
Strategic collaborations with pharmaceutical and biotechnology companies:
The Pasteur Institute was founded in 1887 following Louis Pasteur's successful development of a rabies vaccine. The original mission was to study infectious diseases and develop vaccines, but the institute's scope has expanded dramatically over more than a century.
Pasteur Institute researchers have contributed to multiple Nobel Prizes:
While infectious disease research remains central to the institute's mission, the recognition that neuroinflammation plays a key role in many neurodegenerative diseases has led to expansion into this field. The expertise in immunology, protein biology, and disease mechanisms translates naturally to studying Alzheimer's, Parkinson's, and prion diseases.
The institute provides state-of-the-art core facilities:
Genomics Platform: Next-generation sequencing, single-cell genomics, epigenomics
Proteomics Platform: Mass spectrometry, protein sequencing, interactomics
Imaging Platform: Confocal microscopy, electron microscopy, super-resolution, live-cell imaging
Animal Facility: Specific pathogen-free (SPF) animal colonies, genetically engineered models
Clinical Research Unit: Phase I-II clinical trial capabilities
The institute maintains repositories of:
Computational infrastructure for:
Single-Cell Analysis: Understanding cellular heterogeneity in neurodegeneration through single-cell genomics and proteomics[@combrisson2023].
Gene Editing: CRISPR approaches for neurological disorders, including both therapeutic development and disease modeling[@rodriguez2024].
Stem Cell Models: iPSC-derived neurons and glia for disease modeling and drug screening[@marschall2023].
Therapeutic Development: Novel compounds for neurodegenerative diseases, including prion disease therapeutics and immunomodulatory approaches.
The institute receives funding from multiple sources:
Pasteur Institute researchers publish extensively in leading journals:
The institute has trained numerous leaders in neuroscience:
Contributions to public health include: